Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Changing Trends in Sickle Cell Disease-Related Mortality in the United States over Four Decades

Kristine Karkoska, Patrick T. McGann

Blood (2023) 142 (Supplement 1): 925.

https://doi.org/10.1182/blood-2023-177988

Published: 2023

Journal Articles

Non-Invasive Screening for Sickle Cell Disease Using Only a Smartphone Application

Eudorah Vital, Meredith H. LiCalzi, Robert Mannino, Patrick T. McGann, Wilbur Lam

Blood (2023) 142 (Supplement 1): 2286.

https://doi.org/10.1182/blood-2023-189810

Published: 2023

Journal Articles

Assessment of Emergency Department Care for Patients with Acute Pain Crisis after the Formation of a Multidisciplinary Team

Taneisha Wilson, Katie Cherenzia, John L. Reagan, Dana L. Guyer, Catherine Trimbur, Jessica Nagy, Jon Meideros, Andrew Buksar, Priscilla Eskridge, David Gardner, Ilse Jenouri, Patrick T. McGann

Blood (2022) 140 (Supplement 1): 5013–5014.

https://doi.org/10.1182/blood-2022-170951

Published: 2022

Journal Articles

Optimizing Dose and Limiting Laboratory Monitoring of Hydroxyurea in Africa: Design of the Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa (PUSH-UP) Trial

Patrick T. McGann, Christine Briscoe, Margarida Muhongo, Rui Pascoal, J. Ray Tanzer, Roxanne Wood, Anastacia da Conceicao Nguvela, Eugenia Alberto Mateus

Blood (2022) 140 (Supplement 1): 5422–5423.

https://doi.org/10.1182/blood-2022-163202

Published: 2022

Journal Articles

Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial

Abena Appiah-Kubi, Seethal A Jacob, Matthew M. Heeney, Clark Brown, Susan E. Creary, Christine R Hollenkamp, Emily Riehm Meier, Omar Niss, Connie M. Piccone, Maa-Ohui Quarmyne, Charles T. Quinn, Allison Remiker, Kay L Saving, Min Dong, Patrick T. McGann

Blood (2022) 140 (Supplement 1): 5416–5417.

https://doi.org/10.1182/blood-2022-158623

Published: 2022

Journal Articles

Emergency Department Experience and the Use of Non-Pharmacologic Treatment for Acute Pain Among Patients with Sickle Disease

Elleen Kim, Taneisha Wilson, Malek Mitchell, Patrick T. McGann

Blood (2022) 140 (Supplement 1): 13073–13074.

https://doi.org/10.1182/blood-2022-171065

Published: 2022

Journal Articles

Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT)

Min Dong, Angela Good, Alexander A. Vinks, Russell E. Ware, Patrick T. McGann

Blood (2022) 140 (Supplement 1): 8168–8169.

https://doi.org/10.1182/blood-2022-171022

Published: 2022

Journal Articles

Comparison of Sickle SCAN and Hemotype SC As Point-of-Care Newborn Screening Diagnostics for Sickle Cell Disease in Luanda, Angola

Halimat Shadia Olaniyan, Christine Briscoe, Brigida Santos, Rui Pascoal, António Armando, Patrick T. McGann

Blood (2021) 138 (Supplement 1): 913.

https://doi.org/10.1182/blood-2021-151028

Published: 2021

Journal Articles

Early Hydroxyurea Use May be Neuroprotective in Children with Sickle Cell Anemia

Kristine Anne Karkoska, Amanda Pfeiffer, Patrick T. McGann

Blood (2021) 138 (Supplement 1): 979.

https://doi.org/10.1182/blood-2021-154272

Published: 2021

Journal Articles

Hydroxyurea Reduces the Transfusion Burden in Children with Sickle Cell Anemia: The Reach Experience

Alexandra Power-Hays, George A. Tomlinson, Leon Tshilolo, Brigida Santos, Thomas N. Williams, Peter Olupot-Olupot, Patrick T. McGann, Banu Aygun, Adam Lane, Susan E. Stuber, Teresa Latham, Russell E. Ware

Blood (2021) 138 (Supplement 1): 11.

https://doi.org/10.1182/blood-2021-146632

Published: 2021

Journal Articles

Longitudinal Analysis of Hydroxyurea and Fetal Hemoglobin in Adult Patients with Sickle Cell Anemia

Aryeh Pelcovits, Giancarlo Riotto, Katie Cherenzia, Patrick T. McGann, John L Reagan

Blood (2021) 138 (Supplement 1): 2054.

https://doi.org/10.1182/blood-2021-153890

Published: 2021

Journal Articles

Building Capacity and Assessing Stroke Risk with Transcranial Doppler Ultrasonography in Sub-Saharan Africa: The Reach Experience

Brigida Santos, MD, Maria Nakafeero, Adam Lane, PhD, Leon Tshilolo, MDPhD, Thomas N. Williams, MDPhD, Peter Olupot-Olupot, MDPhD, Janet Adams, Banu Aygun, MD, Susan E. Stuber, MA, George A. Tomlinson, PhD BSc, MSc, Teresa Latham, MA, Patrick T. McGann, MD MS, Russell E. Ware, MD PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142318

Published: 2020

Journal Articles

Optimizing Hydroxyurea Therapy with Reduced Laboratory Monitoring for Children with Sickle Cell Anemia in Sub-Saharan Africa: The Reach Experience

Banu Aygun, MD, George A. Tomlinson, PhD BSc, MSc, Patrick T. McGann, MD MS, Leon Tshilolo, MDPhD, Thomas N. Williams, MDPhD, Peter Olupot-Olupot, MDPhD, Brigida Santos, MD, Susan E. Stuber, MA, Adam Lane, PhD, Teresa Latham, MA, Russell E. Ware, MD PhD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-134180

Published: 2020

Journal Articles

Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia

Alina Sadaf, MD, Charles T. Quinn, MD, Jennifer B Korpik, Amanda Pfeiffer, BS, MA, Mary Reynaud, MA, MT(ASCP), Omar Niss, MD, Punam Malik, MD, Russell E. Ware, MD PhD, Theodosia A. Kalfa, MD PhD, Patrick T. McGann, MD MS

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137070

Published: 2020

Journal Articles

Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-143139

Published: 2020

Journal Articles

Increased Hydroxyurea Prescribing Practices over Ten Years with Improved Clinical Outcomes in Children with Sickle Cell Anemia: A Single Center's Experience

Kristine Anne Karkoska, MD, Kevin E Todd, Jr., MD, Kelly Clapp, NP, Lynette Fenchel, NP, Theodosia A. Kalfa, MD PhD, Punam Malik, MD, Omar Niss, MD, Charles T. Quinn, MD, Russell E. Ware, MD PhD, Patrick T. McGann, MD MS

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-138754

Published: 2020

Journal Articles

Characterization of Community-Based Socioeconomic Factors, Utilization, and Adherence in Children with Sickle Cell Disease

Ronay Thomas, BS, Patrick T. McGann, MD, Andrew Beck, MD MPH, Amanda Pfeiffer, Kyesha M James, BS

Blood (2019) 134 (Supplement_1): 4686.

https://doi.org/10.1182/blood-2019-130637

Published: 2019

Journal Articles

Academic Challenges and Concerns for Children with Sickle Cell Disease: Analysis of a Hospital-Based School Intervention Program

Kristine Anne Karkoska, MD, Kenneth Haber, MS, Patrick T. McGann, MD

Blood (2019) 134 (Supplement_1): 2165.

https://doi.org/10.1182/blood-2019-128279

Published: 2019

Journal Articles

Effects of Hydroxyurea Treatment on Malaria Infections in Sub-Saharan Africa

Peter Olupot-Olupot, George A. Tomlinson, PhD BSc, MSc, Teresa S. Latham, MA, Patrick T. McGann, MD, Brigida Santos, Banu Aygun, MD, Susan Stuber, MA, Leon Tshilolo, MD PhD, Adam Lane, PhD, Thomas N. Williams, Russell E. Ware, MD PhD

Blood (2019) 134 (Supplement_1): 522.

https://doi.org/10.1182/blood-2019-129251

Published: 2019

Journal Articles

Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption

Alexander A Boucher, MD, Min Dong, PhD, Anu Marahatta, PhD, Adriane Hausfeld, Thad A. Howard, MS, Jaimie D Nathan, MD, Alexander A. Vinks, PharmD, PhD FCP, Patrick T. McGann, MD, Russell E. Ware, MD PhD, Lori Luchtman-Jones, MD

Blood (2019) 134 (Supplement_1): 4893.

https://doi.org/10.1182/blood-2019-127378

Published: 2019

NARROW

Changing Trends in Sickle Cell Disease-Related Mortality in the United States over Four Decades

Non-Invasive Screening for Sickle Cell Disease Using Only a Smartphone Application

Assessment of Emergency Department Care for Patients with Acute Pain Crisis after the Formation of a Multidisciplinary Team

Optimizing Dose and Limiting Laboratory Monitoring of Hydroxyurea in Africa: Design of the Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa (PUSH-UP) Trial

Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial

Emergency Department Experience and the Use of Non-Pharmacologic Treatment for Acute Pain Among Patients with Sickle Disease

Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT)

Comparison of Sickle SCAN and Hemotype SC As Point-of-Care Newborn Screening Diagnostics for Sickle Cell Disease in Luanda, Angola

Early Hydroxyurea Use May be Neuroprotective in Children with Sickle Cell Anemia

Hydroxyurea Reduces the Transfusion Burden in Children with Sickle Cell Anemia: The Reach Experience

Longitudinal Analysis of Hydroxyurea and Fetal Hemoglobin in Adult Patients with Sickle Cell Anemia

Building Capacity and Assessing Stroke Risk with Transcranial Doppler Ultrasonography in Sub-Saharan Africa: The Reach Experience

Optimizing Hydroxyurea Therapy with Reduced Laboratory Monitoring for Children with Sickle Cell Anemia in Sub-Saharan Africa: The Reach Experience

Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia

Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment

Increased Hydroxyurea Prescribing Practices over Ten Years with Improved Clinical Outcomes in Children with Sickle Cell Anemia: A Single Center's Experience

Characterization of Community-Based Socioeconomic Factors, Utilization, and Adherence in Children with Sickle Cell Disease

Academic Challenges and Concerns for Children with Sickle Cell Disease: Analysis of a Hospital-Based School Intervention Program

Effects of Hydroxyurea Treatment on Malaria Infections in Sub-Saharan Africa

Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only